Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat as a Single Agent in Subjects With Advanced Solid Tumors or With B-cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma

NCT01897571 is registered in ClinicalTrials.gov with Epizyme, Inc. as lead sponsor.

NCT NCT01897571
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01897571 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat as a Single Agent in Subjects With Advanced Solid Tumors or With B-cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma
Lead sponsor
Epizyme, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
June 13, 2013
Completion date
November 2, 2021
Enrollment
400 (actual)
Sites
52

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors (phase 1), b-cell lymphomas (phase 1), diffuse large b-cell lymphoma (phase 2), follicular lymphoma (phase 2), primary mediastinal large b-cell lymphoma, transformed follicular lymphoma